| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
The molecular targets of (E)-Ferulic acid methyl ester include COX (cyclooxygenase), suggesting potential anti-inflammatory activity. The compound's antioxidant activity is mediated through its ability to scavenge DPPH and ABTS⁺ free radicals. As a cinnamic acid ester, it may also interact with other enzymes and signaling pathways involved in oxidative stress and inflammation. Its guaiacol structure contributes to its radical scavenging properties. The compound is functionally related to ferulic acid.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that (E)-Ferulic acid methyl ester exhibits strong DPPH and ABTS⁺ radical scavenging activities. The compound functions as an antioxidant by scavenging free radicals. It shows activity in standard antioxidant assays, indicating its potential for protecting cells from oxidative damage. The compound's COX targeting suggests potential anti-inflammatory activity, though specific IC₅₀ values for COX inhibition are not provided. These in vitro activities support its potential for oxidative stress and inflammation research.
|
| ln Vivo |
In vivo studies of (E)-Ferulic acid methyl ester have not been extensively reported in the available literature. As an antioxidant and plant metabolite, it may have potential benefits in models of oxidative stress and inflammation. The compound's COX targeting suggests possible anti-inflammatory effects in vivo. However, specific in vivo efficacy data in animal models are not detailed. Further studies are needed to evaluate its pharmacokinetics and efficacy.
|
| Enzyme Assay |
Typical in vitro antioxidant assays for (E)-Ferulic acid methyl ester include DPPH and ABTS radical scavenging assays. For the DPPH assay, the compound is incubated with DPPH radical solution at various concentrations for 30 minutes at room temperature, and absorbance is measured at 517 nm. For the ABTS assay, ABTS radical cation is generated and incubated with the compound, and absorbance is measured at 734 nm. IC₅₀ values are calculated from dose-response curves. COX inhibition assays involve incubating the enzyme with the compound and substrate, and measuring prostaglandin production.
|
| Cell Assay |
Cell-based assays for (E)-Ferulic acid methyl ester typically involve treating cultured cells (e.g., macrophages, endothelial cells) with the compound at concentrations ranging from 1-100 µM for 24-48 hours. ROS levels are measured using fluorescent probes. Inflammatory markers such as COX-2, TNF-α, and IL-6 are assessed by ELISA or Western blot. Cell viability is assessed by MTT assay. These cell-based systems allow for detailed analysis of the compound's antioxidant and anti-inflammatory effects.
|
| Animal Protocol |
In vivo animal experiments for (E)-Ferulic acid methyl ester are not detailed in the available literature. For anti-inflammatory studies, typical animal models include carrageenan-induced paw edema or LPS-induced systemic inflammation in rodents. The compound is administered orally or intraperitoneally at doses ranging from 10-100 mg/kg. Inflammatory markers in serum and tissues are measured. Antioxidant effects are assessed by measuring oxidative stress markers in tissues. However, such studies have not been reported for this specific compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for (E)-Ferulic acid methyl ester are limited. As a methyl ester with a molecular weight of 208.21 g/mol, it may be hydrolyzed to ferulic acid, which is known to be absorbed and metabolized. The compound has a LogP of 1.4 and a density of 1.2±0.1 g/cm³. As a small lipophilic molecule, it would be expected to have good oral bioavailability. However, detailed PK parameters including Cmax, Tmax, half-life, and bioavailability are not available in the consulted sources.
|
| Toxicity/Toxicokinetics |
Toxicological data for (E)-Ferulic acid methyl ester are limited. As a naturally occurring plant metabolite and antioxidant, it is generally considered to have low toxicity. Ferulic acid derivatives are known to be safe and are used in food and cosmetic products. However, comprehensive toxicological studies for the methyl ester have not been reported. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
Trans-methylferulate is a cinnamic acid ester, a methyl ester of ferulic acid. It has been isolated from Pisonia aculeata. It is a plant metabolite. It is a cinnamic acid ester, a methyl ester, and one of the guaiacol compounds. It is functionally related to ferulic acid. Methylferulate has been reported in Meum athamanticum, Iris milesii, and other organisms with relevant data. See also: Black cohosh (partial).
(E)-Ferulic acid methyl ester is a naturally occurring cinnamic acid ester and plant metabolite isolated from Pisonia aculeata. It exhibits strong antioxidant activity through DPPH and ABTS radical scavenging and targets COX, suggesting anti-inflammatory potential. The compound is a guaiacol derivative and is used in research on oxidative stress and inflammation. It is not approved for any clinical indication and is for research use only. |
| Molecular Formula |
C11H12O4
|
|---|---|
| Molecular Weight |
208.21
|
| Exact Mass |
208.073
|
| CAS # |
22329-76-6
|
| Related CAS # |
Ferulic acid methyl ester;2309-07-1
|
| PubChem CID |
5357283
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
338.1±27.0 °C at 760 mmHg
|
| Melting Point |
63-65ºC(lit.)
|
| Flash Point |
130.4±17.2 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.575
|
| LogP |
1.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
15
|
| Complexity |
237
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N/A
|
| InChi Key |
AUJXJFHANFIVKH-GQCTYLIASA-N
|
| InChi Code |
InChI=1S/C11H12O4/c1-14-10-7-8(3-5-9(10)12)4-6-11(13)15-2/h3-7,12H,1-2H3/b6-4+
|
| Chemical Name |
methyl (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8028 mL | 24.0142 mL | 48.0284 mL | |
| 5 mM | 0.9606 mL | 4.8028 mL | 9.6057 mL | |
| 10 mM | 0.4803 mL | 2.4014 mL | 4.8028 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
